Clinical Study

Gct1015-05/Gog-3024- A Phase 1B/2 Open-Label Trial Of Tisotumab Vedotin (Humax®-Tf-Adc) Monotherapy And In Combination With Other Agents In Subjects With Recurrent Or Stage Ivb Cervical Cancer

Posted Date: May 22, 2020

  • Investigator: Amanda Jackson
  • Specialties: Cancer, Cervical Cancer, Oncology
  • Type of Study: Drug

The goal of this study is to establish the MTD and RP2D of tisotumab vedotin in combination in subjects with advanced cervical cancer


To Be Eligible: Must Have Squamous, Adenosquamous, Or Adenocarcinoma Of The Cervix, Measurable Disease, Ecog 0-1, Life Expectancy Of = 3 Months, No Signs Of Gi Obstruction, No Active Autoimmune Disorder Or Cardiovascular Disease, No Prior Malignancy Within 5 Years


Cervical Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.